Vitamin D Therapy for Chronic Kidney Disease

Seminars in Nephrology

Volumn 29, Issue 1, 2009, Pages 85-93

  Bhan, Ishir ^a   Thadhani, Ravi ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chronic kidney disease; hemodialysis; hyperparathyroidism; survival; vitamin D

Indexed keywords

ALFACALCIDOL; CALCIMIMETIC AGENT; CALCITRIOL; CATHELICIDIN; CINACALCET; DOXERCALCIFEROL; ERGOCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; VITAMIN D;

ARTICLE; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE COURSE; GLOMERULOSCLEROSIS; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; INTRAVENOUS CATHETER; METABOLIC BONE DISEASE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION;

AGED; ANIMALS; HUMANS; HYPERPARATHYROIDISM; KIDNEY FAILURE, CHRONIC; MALE; VITAMIN D; VITAMINS;

EID: 58049117742     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2008.10.010     Document Type: Article

References (79)

1. Brunette M.G., Chan M., Ferriere C., and Roberts K.D. Site of 1,25(OH)2 vitamin D3 synthesis in the kidney. Nature 276 (1978) 287-289
2. Takeyama K., Kitanaka S., Sato T., et al. 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. Science 277 (1997) 1827-1830
3. Holick M.F., Schnoes H.K., and DeLuca H.F. Identification of 1,25-dihydroxycholecalciferol, a form of vitamin D3 metabolically active in the intestine. Proc Natl Acad Sci U S A 68 (1971) 803-804
4. Holick M.F. Vitamin D deficiency. N Engl J Med 357 (2007) 266-281
5. Suda T., Ueno Y., Fujii K., and Shinki T. Vitamin D and bone. J Cell Biochem 88 (2003) 259-266
6. DeLuca H.F. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80 Suppl (2004) 1689S-1696S
7. Gal-Moscovici A., and Sprague S.M. Role of vitamin D deficiency in chronic kidney disease. J Bone Miner Res 22 Suppl 2 (2007) V91-V94
8. Block G.A., Hulbert-Shearon T.E., Levin N.W., and Port F.K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31 (1998) 607-617
9. US Renal Data System. USRDS 2007 annual data report (2007), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
10. Steddon S.J., and Cunningham J. Calcimimetics and calcilytics-fooling the calcium receptor. Lancet 365 (2005) 2237-2239
11. Li Y.C., Kong J., Wei M., et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110 (2002) 229-238
12. Zhou C.L., Lu F.X., Cao K.X., et al. Calcium-independent and 1,25(OH)(2)D(3)-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 74 (2008) 141-143
13. Yamamoto T., Kozawa O., Tanabe K., et al. 1,25-dihydroxyvitamin D3 stimulates vascular endothelial growth factor release in aortic smooth muscle cells: role of p38 mitogen-activated protein kinase. Arch Biochem Biophys 398 (2002) 1-6
14. Teng M., Wolf M., Ofsthun M.N., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16 (2005) 1115-1125
15. Teng M., Wolf M., Lowrie E., et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349 (2003) 446-456
16. Shoji T., Shinohara K., Kimoto E., et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19 (2004) 179-184
17. Melamed M.L., Eustace J.A., Plantinga L., et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 70 (2006) 351-357
18. Tentori F., Hunt W.C., Stidley C.A., et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70 (2006) 1858-1865
19. Kalantar-Zadeh K., Kuwae N., Regidor D.L., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70 (2006) 771-780
20. Kovesdy C.P., Ahmadzadeh S., Anderson J.E., and Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 168 (2008) 397-403
21. Wolf M., Betancourt J., Chang Y., et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 19 (2008) 1379-1388
22. Palmer S.C., McGregor D.O., Macaskill P., et al. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 147 (2007) 840-853
23. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 (2000) 1478-1483
24. Goldsmith D.J., Covic A., Sambrook P.A., and Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 77 (1997) 37-43
25. Milliner D.S., Zinsmeister A.R., Lieberman E., and Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 38 (1990) 931-936
26. Jono S., Nishizawa Y., Shioi A., and Morii H. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 98 (1998) 1302-1306
27. Zittermann A., Schleithoff S.S., and Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 94 (2005) 483-492
28. Detrano R., Guerci A.D., Carr J.J., et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 358 (2008) 1136-1145
29. Blacher J., Guerin A.P., Pannier B., et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99 (1999) 2434-2439
30. London G.M., Guerin A.P., Marchais S.J., et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18 (2003) 1731-1740
31. Moe S.M., O'Neill K.D., Reslerova M., et al. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant 19 (2004) 2387-2393
32. Merx M.W., Schafer C., Westenfeld R., et al. Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. J Am Soc Nephrol 16 (2005) 3357-3364
33. Ahmed A., Rich M.W., Sanders P.W., et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol 99 (2007) 393-398
34. Mizobuchi M., Finch J.L., Martin D.R., and Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. 72 (2007) 709-715
35. Tukaj C., Kubasik-Juraniec J., and Kraszpulski M. Morphological changes of aortal smooth muscle cells exposed to calcitriol in culture. Med Sci Monit 6 (2000) 668-674
36. Andress D.L. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 69 (2006) 33-43
37. Drissi H., Pouliot A., Koolloos C., et al. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 274 (2002) 323-333
38. Andersson P., Rydberg E., and Willenheimer R. Primary hyperparathyroidism and heart disease-a review. Eur Heart J 25 (2004) 1776-1787
39. Rostand S.G., and Drueke T.B. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56 (1999) 383-392
40. Amann K., Ritz E., Wiest G., Klaus G., and Mall G. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4 (1994) 1814-1819
41. Davies M.R., and Hruska K.A. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 60 (2001) 472-479
42. Xiang W., Kong J., Chen S., et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol 288 (2005) E125-E132
43. Wu J., Garami M., Cheng T., and Gardner D.G. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 97 (1996) 1577-1588
44. Bodyak N., Ayus J.C., Achinger S., et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A 104 (2007) 16810-16815
45. Park C.W., Oh Y.S., Shin Y.S., et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 33 (1999) 73-81
46. Zhang Z., Sun L., Wang Y., et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 73 (2008) 163-171
47. Kautzky-Willer A., Pacini G., Barnas U., et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 47 (1995) 200-206
48. Aihara K., Azuma H., Akaike M., et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 279 (2004) 35798-35802
49. Mak R.H. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 53 (1998) 1353-1357
50. Chonchol M., and Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int 71 (2007) 134-139
51. Martins D., Wolf M., Pan D., et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 167 (2007) 1159-1165
52. Edfeldt K., Agerberth B., Rottenberg M.E., et al. Involvement of the antimicrobial peptide LL-37 in human atherosclerosis. Arterioscler Thromb Vasc Biol 26 (2006) 1551-1557
53. Zasloff M. Inducing endogenous antimicrobial peptides to battle infections. Proc Natl Acad Sci U S A 103 (2006) 8913-8914
54. Zasloff M. Innate immunity, antimicrobial peptides, and protection of the oral cavity. Lancet 360 (2002) 1116-1117
55. Ganz T. Immunology. Versatile defensins. Science 298 (2002) 977-979
56. Hancock R.E., and Scott M.G. The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci U S A 97 (2000) 8856-8861
57. Andreu D., and Rivas L. Animal antimicrobial peptides: an overview. Biopolymers 47 (1998) 415-433
58. Sorensen O., Cowland J.B., Askaa J., and Borregaard N. An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma. J Immunol Methods 206 (1997) 53-59
59. Nizet V., Ohtake T., Lauth X., et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414 (2001) 454-457
60. Bals R., Weiner D.J., Moscioni A.D., Meegalla R.L., and Wilson J.M. Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun 67 (1999) 6084-6089
61. Wang T.T., Nestel F.P., Bourdeau V., et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 173 (2004) 2909-2912
62. Martineau A.R., Wilkinson K.A., Newton S.M., et al. IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol 178 (2007) 7190-7198
63. Gombart A.F., Borregaard N., and Koeffler H.P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 19 (2005) 1067-1077
64. Yim S., Dhawan P., Ragunath C., Christakos S., and Diamond G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3). J Cyst Fibros 6 (2007) 403-410
65. Gombart A.F., O'Kelly J., Saito T., and Koeffler H.P. Regulation of the CAMP gene by 1,25(OH)2D3 in various tissues. J Steroid Biochem Mol Biol 103 (2007) 552-557
66. Liu P.T., Stenger S., Li H., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311 (2006) 1770-1773
67. Gombart A.F., Bhan I., Borregaard N., et al. Low plasma cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in hemodialysis. Clin Infect Dis (2008) (in press)
68. Yu S., and Cantorna M.T. The vitamin D receptor is required for iNKT cell development. Proc Natl Acad Sci U S A 105 (2008) 5207-5212
69. Chen S., Sims G.P., Chen X.X., et al. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179 (2007) 1634-1647
70. Reichel H., Koeffler H.P., Tobler A., and Norman A.W. 1 alpha,25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci U S A 84 (1987) 3385-3389
71. Tsoukas C.D., Provvedini D.M., and Manolagas S.C. 1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. Science 224 (1984) 1438-1440
72. Schwarz U., Amann K., Orth S.R., et al. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 53 (1998) 1696-1705
73. Hirata M., Makibayashi K., Katsumata K., et al. 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. Nephrol Dial Transplant 17 (2002) 2132-2137
74. Kuhlmann A., Haas C.S., Gross M.L., et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 286 (2004) F526-F533
75. Uyar M., Sezer S., Arat Z., et al. 1,25-dihydroxyvitamin D(3) therapy is protective for renal function and prevents hyperparathyroidism in renal allograft recipients. Transplant Proc 38 (2006) 2069-2073
76. LaClair R.E., Hellman R.N., Karp S.L., et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 45 (2005) 1026-1033
77. Wolf M., Shah A., Gutierrez O., et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72 (2007) 1004-1013
78. Zisman A.L., Hristova M., Ho L.T., and Sprague S.M. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 27 (2007) 36-43
79. London G.M., Guérin A.P., Verbeke F.H., et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 18 (2007) 613-620